Viking Therapeutics
VKTX
$33.11
-0.96%
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with its lead programs targeting obesity and non-alcoholic steatohepatitis (NASH). The company is a niche player in the high-growth obesity drug market, distinguished by its dual oral and injectable formulation of VK2735, which has shown superior efficacy and tolerability in early trials. The current investor narrative centers on the upcoming Phase 3 catalyst for VK2735, with Wall Street overwhelmingly bullish on its potential to compete with established players like Eli Lilly and Novo Nordisk, though the stock remains highly speculative and volatile.…
VKTX
Viking Therapeutics
$33.11
Related headlines
Investment Opinion: Should I buy VKTX Today?
Rating: Hold. Viking Therapeutics is a speculative buy for aggressive investors with a high risk tolerance, but for most portfolios, a hold is warranted given the binary risk. The consensus analyst rating is Strong Buy with an average target of $92.58, but the stock's current price already reflects significant optimism.
Supporting Evidence: The primary valuation metric is PB ratio at 6.20x, which is above the industry average of 4.5x. Revenue growth is non-existent, and the company is pre-profit. However, the balance sheet is strong with $165.8 million cash and no debt. The implied upside to the average analyst target is 166%, but the wide range from $34.00 to $125.00 highlights uncertainty. The stock's beta of 0.655 suggests lower volatility, but the 1-month decline of 8.13% indicates recent weakness.
Risks & Conditions: The biggest risks are Phase 3 failure and competitive pressure from Eli Lilly and Novo Nordisk. This Hold would upgrade to Buy if VK2735 Phase 3 data shows superior efficacy and safety, or if the stock pulls back to the 52-week low of $22.96, offering a better entry point. It would downgrade to Sell if the company announces a dilutive offering or if a competitor's drug renders VK2735 obsolete. Overall, the stock is overvalued relative to its fundamentals (zero revenue, negative earnings) but fairly valued relative to its potential if VK2735 succeeds.
Sign up to view all
VKTX 12-Month Price Forecast
The AI assessment is bullish with medium confidence, reflecting the high potential reward balanced by binary risk. The key factors supporting this stance are the unanimous analyst optimism, promising early data, and a strong cash position. However, the lack of revenue, intense competition, and premium valuation temper confidence. The stance would upgrade to high confidence if Phase 3 data confirms best-in-class efficacy, and downgrade to neutral if competitive threats intensify or cash burn accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Viking Therapeutics's 12-month outlook, with a consensus price target around $93.00 and implied upside of +180.9% versus the current price.
Average Target
$93.00
0 analysts
Implied Upside
+180.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$35 - $125
Analyst target range
Viking Therapeutics is covered by 19 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.45 on a 1-5 scale). The average target price is $92.58, implying a massive 166% upside from the current price of $34.79. The distribution shows 0 holds and 0 sells, indicating unanimous bullishness. This extreme optimism is driven by the potential of VK2735 in the obesity market, which could generate billions in peak sales if approved. The target range spans from a low of $34.00 to a high of $125.00, reflecting significant uncertainty. The low target of $34.00 is essentially at the current price, suggesting some analysts see limited upside if trials fail or competition intensifies. The high target of $125.00 implies a 259% upside, assuming best-case scenario for VK2735 approval and commercial success. Recent ratings from firms like HC Wainwright, Canaccord Genuity, and Morgan Stanley have all been positive, with no downgrades. The wide spread between low and high targets (3.7x) underscores the binary nature of the stock's risk-reward profile, typical for a pre-revenue biotech with a single late-stage asset.
Bulls vs Bears: VKTX Investment Factors
Viking Therapeutics presents a high-risk, high-reward opportunity typical of a pre-revenue biotech. The bull case rests on VK2735's potential to capture a share of the massive obesity market, supported by unanimous analyst optimism and a strong balance sheet. However, the bear case highlights zero revenue, widening losses, a premium valuation, and fierce competition from established players. The single most important tension is the binary outcome of Phase 3 trials: success could propel the stock toward analyst targets, while failure could lead to a 34%+ decline. Currently, the bull case has stronger evidence given the early efficacy data and market enthusiasm, but the risk is substantial.
Bullish
- Massive Upside to Analyst Targets: The consensus analyst target price is $92.58, implying a 166% upside from the current price of $34.79. The high target of $125.00 suggests a potential 259% gain, reflecting strong conviction in VK2735's commercial prospects.
- Promising Obesity Drug Candidate: VK2735 has shown superior efficacy and tolerability in early trials, with a dual oral and injectable formulation that could compete with Eli Lilly's Zepbound and Novo Nordisk's Wegovy. The obesity market is projected to reach $100 billion by 2030, offering a massive addressable opportunity.
- Strong Balance Sheet with No Debt: Viking has $165.8 million in cash, a current ratio of 9.33, and negligible debt-to-equity of 0.0002. This provides a multi-year runway to fund Phase 3 trials without immediate dilution risk.
- Unanimous Analyst Support: All 19 analysts rate the stock a 'Strong Buy' with a mean recommendation of 1.45 on a 1-5 scale. There are zero holds or sells, indicating extreme conviction in the pipeline.
Bearish
- Zero Revenue and Deep Losses: Viking has no revenue and reported a net loss of $157.7 million in Q4 2025, with R&D spending surging to $153.5 million. The company is entirely dependent on clinical success, with no path to profitability until potential approval.
- Premium Valuation with Binary Risk: The price-to-book ratio of 6.20x is 38% above the biotech industry average of 4.5x and near the high end of its historical range (1.27x-9.73x). Any negative trial data could trigger a sharp de-rating toward the 52-week low of $22.96, a 34% downside.
- Intense Competition from Big Pharma: Eli Lilly's retatrutide recently demonstrated superior efficacy in Phase 3, and Novo Nordisk remains dominant. Viking must not only prove efficacy but also differentiate in a crowded market with deep-pocketed incumbents.
- High Short Interest and Volatility: The short ratio is 8.48 days to cover, indicating significant bearish positioning. The stock has a 1-month decline of 8.13% and a 52-week max drawdown of 45.14%, highlighting its speculative nature.
VKTX Technical Analysis
Viking Therapeutics is in a sustained uptrend over the past year, with a 1-year price change of +3.85%, significantly underperforming the S&P 500's +16.47% gain. The current price of $34.79 sits at 80.7% of its 52-week range ($22.96 to $43.15), indicating it is closer to the highs but not overextended. This positioning suggests the stock retains upward momentum but faces resistance near the 52-week high, with potential for a breakout if catalysts materialize. Short-term momentum shows a mixed picture: the 1-month change is -8.13%, while the 3-month change is +6.23%, indicating a recent pullback from a stronger intermediate-term trend. The 1-month decline contrasts with the 1-year uptrend, suggesting a temporary correction rather than a reversal, especially given the stock's beta of 0.655, which implies lower volatility than the market. The RSI is not provided, but the volume of 1.84 million shares suggests active trading. Key support is at the 52-week low of $22.96, while resistance is at the 52-week high of $43.15. A breakout above $43.15 would signal a resumption of the uptrend and potentially attract momentum buyers, while a breakdown below $22.96 could indicate a bearish reversal. With a beta of 0.655, the stock is 34.5% less volatile than the S&P 500, which may appeal to risk-averse investors but also limits upside during market rallies.
Beta
0.66
0.66x market volatility
Max Drawdown
-45.1%
Largest decline past year
52-Week Range
$23-$43
Price range past year
Annual Return
-1.8%
Cumulative gain past year
| Period | VKTX Return | S&P 500 |
|---|---|---|
| 1m | -15.1% | -0.7% |
| 3m | +10.4% | +2.9% |
| 6m | +14.0% | +7.2% |
| 1y | -1.8% | +16.9% |
| ytd | -6.5% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VKTX Fundamental Analysis
Viking Therapeutics has zero revenue, as it is a pre-commercial biotech company. The most recent quarterly revenue (Q4 2025) was $0, with a YoY growth rate of 0% (no revenue in prior periods). The company's trajectory is entirely dependent on clinical trial success and eventual commercialization; there is no revenue growth to analyze. The lack of revenue is typical for clinical-stage biotechs, and the investment case hinges on pipeline progress rather than current sales. The company is deeply unprofitable, with a net income of -$157.7 million in Q4 2025 and a trailing twelve-month net loss of -$278.7 million. Gross margin is 0% (no revenue), and operating margin is negative. However, losses are widening: net income worsened from -$35.4 million in Q4 2024 to -$157.7 million in Q4 2025, driven by increased R&D spending ($153.5 million in Q4 2025 vs. $31.0 million in Q4 2024). This reflects the company's ramp-up in clinical trials, which is expected for a late-stage biotech. The balance sheet is strong despite operating losses. As of Q4 2025, the company had $165.8 million in cash and a current ratio of 9.33, indicating ample liquidity. Debt-to-equity is negligible at 0.0002, and free cash flow was -$85.3 million in Q4 2025, but the company has no debt and has raised capital through equity offerings (e.g., $597 million in Q1 2024). ROE is -56.3%, reflecting the net loss relative to shareholders' equity, but this is typical for pre-revenue biotechs.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-278685000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VKTX Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is not applicable (revenue is zero). Instead, we use the price-to-book (PB) ratio as the primary metric, as the company has positive book value. The trailing PB ratio is 6.20x, and the historical PB range over the past year has fluctuated between 1.27x and 9.73x. The current PB of 6.20x is above the midpoint of this range, suggesting the market is pricing in optimistic expectations for future drug approval. Compared to the biotechnology industry average PB of approximately 4.5x (based on sector data), Viking trades at a 38% premium. This premium is justified by the company's promising obesity drug candidate VK2735, which has shown superior efficacy in early trials, and the massive addressable market for obesity treatments. However, the lack of revenue and earnings makes traditional valuation metrics less meaningful. Historically, Viking's PB ratio has ranged from 1.27x (Q2 2022) to 9.73x (Q1 2023), with the current 6.20x near the higher end of its historical band. This indicates that the stock is priced for significant future success, leaving little room for error. If clinical trials disappoint, the stock could de-rate sharply toward the lower end of its historical PB range.
PE
-11.0x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Viking has zero revenue and is deeply unprofitable, with a trailing twelve-month net loss of $278.7 million. R&D expenses have skyrocketed from $30.9 million in Q4 2024 to $153.5 million in Q4 2025, reflecting the ramp-up for Phase 3 trials. While the company has $165.8 million in cash, the cash burn rate is accelerating, and free cash flow was -$85.3 million in Q4 2025 alone. If trials are delayed or fail, the company may need to raise capital through dilutive equity offerings, as it did with a $597 million raise in Q1 2024. The lack of revenue means there is no margin of safety from operations.
Market & Competitive Risks: The stock trades at a PB ratio of 6.20x, a 38% premium to the biotech industry average, implying high expectations for VK2735. Any negative news could compress this multiple toward the historical low of 1.27x. Competition is intense: Eli Lilly's retatrutide has shown superior efficacy in Phase 3, and Novo Nordisk's Wegovy dominates the market. A recent news article highlighted that Eli Lilly's new oral drug Foundayo is expanding the market, but it also increases competitive pressure. The stock's beta of 0.655 suggests lower volatility than the market, but the 1-month relative strength of -8.91% indicates recent underperformance, and the short ratio of 8.48 days signals persistent bearish sentiment.
Worst-Case Scenario: If VK2735 fails in Phase 3 or shows inferior efficacy, the stock could collapse to its 52-week low of $22.96, representing a 34% decline from the current price of $34.79. In a more extreme scenario, if the company runs out of cash and cannot secure financing, the stock could fall below $20. The historical max drawdown of 45.14% suggests that a drop to $19.10 is possible, implying a 45% loss. Investors could lose up to 45% of their investment in a worst-case scenario.
FAQ
The key risks are: 1) Clinical trial failure – VK2735 could fail in Phase 3, leading to a 34%+ decline to the 52-week low of $22.96. 2) Competitive pressure – Eli Lilly and Novo Nordisk have deep resources and superior efficacy data, making it difficult for Viking to capture market share. 3) Financial risk – The company has no revenue and is burning cash rapidly, with a net loss of $157.7 million in Q4 2025. If trials are delayed, it may need to raise capital through dilutive offerings. 4) Valuation risk – The stock trades at a premium PB multiple, leaving little room for error. The most severe risk is trial failure, which could wipe out most of the stock's value.
The 12-month forecast is highly binary. In the bull case (30% probability), the stock could reach $80-$125, driven by positive Phase 3 data and partnership deals. In the base case (40% probability), the stock trades between $50 and $80, reflecting moderate success. In the bear case (30% probability), the stock falls to $23-$34, if trials fail or competition overwhelms. The most likely scenario is the base case, assuming VK2735 shows positive but not best-in-class results. The consensus analyst target of $92.58 aligns with the upper end of the base case. Investors should monitor Phase 3 data as the key catalyst.
VKTX is overvalued based on traditional metrics, with a PB ratio of 6.20x, 38% above the biotech industry average of 4.5x. However, it is undervalued relative to its potential if VK2735 succeeds, as the average analyst target implies a 166% upside. The stock's historical PB range of 1.27x to 9.73x suggests it is near the high end, meaning the market is pricing in optimistic expectations. The valuation implies that investors expect VK2735 to generate billions in peak sales. If trials fail, the stock could de-rate to the lower end of the range, representing a significant downside.
VKTX is a high-risk, high-reward stock suitable for aggressive investors with a long-term horizon and tolerance for volatility. The consensus analyst target of $92.58 implies 166% upside, but the stock is pre-revenue and trades at a premium PB of 6.20x. The biggest downside risk is a Phase 3 failure, which could send the stock to the 52-week low of $22.96, a 34% loss. For investors who believe in VK2735's potential and can stomach a potential 45% drawdown, it could be a good buy at current levels. However, for risk-averse investors, it is better to wait for Phase 3 data or a pullback to a lower entry point.
VKTX is suitable for long-term investment (3-5 years) if VK2735 is approved and commercialized, as the obesity market offers multi-year growth. However, it is also a short-term trading vehicle due to binary catalysts like Phase 3 data. The stock's beta of 0.655 suggests lower volatility than the market, but the 1-month decline of 8.13% and high short interest indicate short-term risk. For long-term investors, a minimum holding period of 3 years is recommended to allow for clinical development and potential approval. Short-term traders should focus on key data readouts and manage risk with stop-losses. The stock does not pay a dividend, so total return depends entirely on price appreciation.